Enhances vascular strength, circulation health, and heart function support.
ARA-290 demonstrates exceptional cardiovascular benefits through its tissue-protective properties, anti-inflammatory effects, and support for cardiac and vascular repair without the erythropoietic risks of EPO. Cardioprotective
Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown significant cardiovascular benefits in clinical trials. Tirzepatide presents a
ARA-290 demonstrates exceptional cardiovascular benefits through its tissue-protective properties, anti-inflammatory effects, and support for cardiac and vascular repair without the erythropoietic risks of EPO. Cardioprotective
Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown significant cardiovascular benefits in clinical trials. Tirzepatide presents a
